Form 4: Leap Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
William Patrick Mcevoy Iii, Chief Investment Officer, a Director and 10% owner of Leap Therapeutics, Inc., reported multiple transactions in common stock on October 12, 2026.
Summary
- In-the-money derivative exercise: acquired 4,938,801 Common Stock at $0.00 ($4,939) on October 12, 2026; holds 29,793,414 after (Indirect).
- In-the-money derivative exercise: disposed of 4,938,801 Pre-Funded Warrant (Right to Buy) at $0.52 ($2,566,201) on October 12, 2026; holds 97,229,007 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
William Patrick Mcevoy Iii — Director, Officer (Chief Investment Officer), 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-12 | In-the-money derivative exercise | Common Stock | 4,938,801 | $0 | $4.9K | 29,793,414 |
| 2026-10-12 | In-the-money derivative exercise | Pre-Funded Warrant (Right to Buy) | 4,938,801 | $1 | $2.6M | 97,229,007 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-12 | In-the-money derivative exercise (4,938,801 shares) |
| 2026-10-12 | In-the-money derivative exercise (4,938,801 shares) |
Keywords
insider transaction, Form 4, CYPH, CYPHERPUNK TECHNOLOGIES INC., neutral, William Patrick Mcevoy Iii
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.